Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authoris…
醫藥資訊與用藥指南
圍繞在售藥品整理的醫學資訊、適應症、用法與安全注意事項。文章會自動關聯相關商品。
Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised
Retsevmo is a cancer medicine for use in patients whose cancer is caused by certain changes in a…
達拉非尼合併曲美替尼或將成為兒童低度膠質瘤的新標準療法 – 癌症治療顧問
Dabrafenib Plus Trametinib Could Be New Standard in Pediatric Low-Grade Glioma Cancer Therapy Ad…
FDA批准達拉非尼聯合曲美替尼用於治療BRAF V600E突變的不可切除轉移性實體瘤 – 藥學時報
FDA Approves Dabrafenib Plus Trametinib for Unresectable, Metastatic Solid Tumors With BRAF V600…
